TNF blockers on every 2026 Oklahoma Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 11 stand-alone Part D plans in Oklahoma cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
11 plans, cheapest premium first. Scroll sideways for all of them →
| Drug | Blue Cross MedicareRx Basic$0.00/moS5715-015 | Humana Basic Rx Plan$0.00/moS5884-144 | Wellcare Value Script$5.60/moS4802-156 | Wellcare Classic$5.70/moS4802-014 | Humana Value Rx Plan$33.70/moS5884-202 | HealthSpring Extra Rx$65.40/moS5617-373 | AARP Medicare Rx Saver from UHC$82.40/moS5921-368 | Humana Premier Rx Plan$108.60/moS5884-169 | AARP Medicare Rx Preferred from UHC$121.00/moS5921-404 | HealthSpring Assurance Rx$126.50/moS5617-113 | Blue Cross MedicareRx Value$167.30/moS5715-010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Humiraadalimumab | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| adalimumab biosimilarsadalimumab-adaz, -fkjp, -aacf and others | Not covered | Tier 5PA25%QL 0.2/28d | Tier 5PA25%QL 4/28d | Tier 5PA25%QL 4/28d | Tier 5PA26%QL 0.2/28d | Not covered | Tier 5PA25% | Tier 5PA33%QL 0.2/28d | Tier 5PA31% | Not covered | Not covered |
| Hadlimaadalimumab-bwwd | Tier 5PA25%QL 2.4/28d | Not covered | Not covered | Not covered | Not covered | Tier 5PA25%QL 2.4/28d | Not covered | Not covered | Not covered | Tier 5PA25%QL 2.4/28d | Tier 5PA25%QL 2.4/28d |
| Hyrimozadalimumab-adaz | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Cyltezoadalimumab-adbm | Not covered | Not covered | Tier 5PA25%QL 4/28d | Tier 5PA25%QL 4/28d | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Simlandiadalimumab-ryvk | Tier 5PA25%QL 3/28d | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Tier 5PA25%QL 3/28d |
| Yuflymaadalimumab-aaty | Not covered | Not covered | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 2/28d | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Amjevitaadalimumab-atto | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Enbreletanercept | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 8/28d | Tier 5PA25%QL 8/28d | Tier 5PA25%QL 8/28d | Tier 5PA26%QL 8/28d | Tier 5PA25%QL 8/28d | Tier 5PA25%QL 4/28d | Tier 5PA33%QL 8/28d | Tier 5PA31%QL 4/28d | Tier 5PA25%QL 8/28d | Tier 5PA25%QL 2/28d |
| Cimziacertolizumab pegol | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Simponigolimumab | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.